Diffuse cutaneous systemic sclerosis
MONDO:0016356Diffuse cutaneous systemic sclerosis (dcSSc) is a subtype of Systemic Sclerosis (SSc) characterized by truncal and acral skin fibrosis with an early and significant incidence of diffuse involvement (interstitial lung disease, oliguric renal failure, diffuse gastrointestinal disease, and myocardial involvement).
Also known as: dSSc, diffuse cutaneous systemic scleroderma, progressive cutaneous systemic scleroderma, progressive cutaneous systemic sclerosis, DcSSc
66 clinical trials for this condition and its sub-types, 30 tagged with Diffuse cutaneous systemic sclerosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug hope for scleroderma patients with lung complications
Disease control OngoingThis study tests an experimental drug called ifetroban in 34 adults with a severe form of scleroderma (diffuse cutaneous systemic sclerosis) or scleroderma-related lung disease (pulmonary arterial hypertension). The main goal is to see if the drug is safe and whether it can impro…
Phase 2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One-Time cell therapy aims to tame tough scleroderma
Disease control OngoingThis study tests a new treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with severe scleroderma that hasn't improved with standard care. About 96 participants will receive either this one-time cell therapy or the current drug rituximab.…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug aims to slow lung damage in rare autoimmune disease
Disease control OngoingThis phase 2 trial tests whether tulisokibart can safely slow lung scarring in people with systemic sclerosis and interstitial lung disease. About 154 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces the yearly decline in lung fu…
Phase 2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for rare autoimmune disease: baricitinib trial underway
Disease control OngoingThis phase 4 trial tests whether baricitinib, a drug already used for rheumatoid arthritis, can help people with systemic sclerosis—a rare disease that causes skin thickening and organ damage. Sixty participants will receive either baricitinib or standard treatment for 24 weeks, …
Phase 4 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on lupus and scleroderma in first human test
Disease control OngoingThis early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC